Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer.

NPJ genomic medicine·2026

Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026

Same author

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

British journal of haematology·2026

Same author

Precision-guided therapy in H3K27-altered diffuse midline glioma.

Nature communications·2026

Same author

Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.

Molecular cancer therapeutics·2026

Same author

Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: Sep 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Donor T cells for CAR T cell therapy.

Tiffany C Y Tang^1,2, Ning Xu^3,4, Robert Nordon⁵

¹Graduate School of Biomedical Engineering, Faculty of Engineering, UNSW Sydney, Sydney, NSW, Australia. tiffany.tang@unsw.edu.au.

Biomarker Research

|April 2, 2022

Summary

Universal donor CAR T cells offer a promising solution for broader access to cellular therapies. These "off-the-shelf" treatments aim to overcome limitations of patient-specific cell manufacturing, enhancing accessibility for cancer patients.

Keywords:

CRISPR-Cas9 Donor CAR T cells GVHD Genome editing TALENs

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Related Experiment Videos

Last Updated: Sep 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Adoptive cell therapy with chimeric antigen receptor (CAR) T cells shows success in hematologic cancers.
Manufacturing patient-derived CAR T cells faces challenges like lymphopenia and tumor cell contamination.
Wider accessibility of CAR T cell therapy is needed for all patients.

Purpose of the Study:

To explore the potential of donor T cells for generating universal CAR T cells.
To address limitations in patient-specific CAR T cell manufacturing.
To enhance the safety and efficacy of CAR T cell therapy.

Main Methods:

Utilizing donor T cells for adoptive immunotherapy.
Employing genome editing tools (TALENs, CRISPR-Cas9) and non-gene editing methods (shRNA, protein expression blockade).
Modifying T cells to abrogate graft-versus-host disease (GVHD) and prevent host rejection.

Main Results:

Donor T cells can be engineered into universal CAR T cells.
Genome editing and other methods enhance CAR T cell safety and efficacy.
Universal CAR T cells offer an "off-the-shelf" therapeutic option.

Conclusions:

Universal donor CAR T cells can overcome manufacturing hurdles of autologous therapies.
Engineered donor T cells provide a readily available and potentially safer alternative for cancer treatment.
This approach broadens the accessibility of advanced cellular immunotherapies.